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Matrix metalloproteinase (MMP) expression and production are associated with
advanced-stage tumor and contribute to tumor progression, invasion and metastases. The cur-
rent study was designed to determine the expression and production ofMMP-2 (gelatinase A)
and MMP-9 (gelatinase B) by human lymphoid tumor cells. Changes in expression and pro-
duction were also investigated during tumor progression of multiple myeloma and mycosis
fungoides. In situ hybridization analysis revealed that lymphoblastic leukemia B cells (SB
cell line), multiple myeloma (MM) cells (U266 cell line) and lymphoblastic leukemia T cells
(CEM and Jurkat cell lines) express constitutively the mRNA for MMP-2 and/or MMP-9. We
demonstrated by gelatin-zymography of cell culture medium that both enzymes were secreted
in their cleaved (activated) form. In situ hybridization of bone marrow plasma cells and gela-
tin-zymography of the medium showed that patients with active MM (diagnosis, relapse,
leukemic progression) express higher levels ofMMP-2 mRNA and protein than patients with
non-active MM (complete/objective response, plateau) and with monoclonal gammopathies
of undetermined significance (MGUS). MMP-9 expression and secretion was similar in all
patient groups. In patients with mycosis fungoides (MF), the expression of MMP-2 and
MMP-9 mRNAs was significantly upregulated with advancing stage, in terms of lesions both
positive for one of two mRNAs and with the greatest intensity of expression. Besides MF
cells, the MMP-2 and/or MMP-9 mRNAs were expressed by some stromal cell populations
(microvascular endothelial cells, fibroblasts, macrophages), suggesting that these cells coop-
erate in the process of tumor invasion. Our studies identify MMPs as an important class of
proteinases involved in the extracellular matrix (ECM) degradation by human lymphoid
tumors, and suggest that MMPs inhibitors may lead to important new treatment for their con-
trol.
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INTRODUCTION
Many enzyme systems are involved in extracellular
proteolytic events. Enzymes belong to one of two
families, namely the serine proteases in particular
plasminogen activator (PA)/plasmin enzymes and
the matrix metalloproteinases (MMPs) (Mignatti and
Rifkin, 1993). MMPs are a family of closely related
zinc-endopeptidases whose principal function is the
degradation of extracellular matrix (ECM) compo-
nents during normal embryo development, morpho-
genesis and tissue remodelling. They are secreted as
zymogen (activated extracellularly), and divided into
three subgroups based on the substrate preference: the
interstitial collagenases, stromelysin and gelatinases
(type IV collagenases), althought all of them recog-
nize overlapping substrate specificity (Massova et al.,
1998).
Type IV collagenases include type IV 72 kDa
(MMP-2 or gelatinase A) and 92 kDa (MMP-9 or
gelatinase B) enzymes. Both MMP-2 and MMP-9
facilitate invasion and metastases because they
degrade type IV, V, VII and X collagens as well as
fibronectin (Mignatti and Rifkin, 1993; Massova et
al., 1998) which are major constituents of the intersti-
tial stroma and the subendothelial basement mem-
brane ECM. Studies in animal models clearly
demonstrated a positive correlation between MMP
expression, invasive behavior and metastatic potential
(Krane, 1994; Coussens and Werb, 1996; Stetler-Ste-
venson et al., 1997; Kanayama et al. 1998).
MMPs production in vivo and in vitro is increased
in response to angiogenic agents (Coussen and Werb,
1996). In some conditions, such as diabetic retinopa-
thy, the involvement of proteinases may be confined
to the process of angiogenesis (Folkman, 1995); in
others, such as cancer (Johnson et al., 1998) and rheu-
matoid arthritis (Gordon et al., 1993; Bottomley et al.,
1998), proteinase activity is thought to be an integral
part of generalized tissue remodelling, as well as of
the formation of new blood vessels. Inhibition of
MMP results in decreased invasion and metastasis of
malignant cell lines (Mignatti and Rifkin, 1993;
Krane, 1994).
The expression ofMMPs has been shown in hema-
tologic cells including polymorphonuclear leuko-
cytes, macrophages and lymphocytes.
Polymorphonuclear leucocyte infiltration and microv-
ascular injury are allmarks the countersign of tissue
remodelling associated with multiple organ failure.
These processes require the concerted action of vari-
ous proteolytic enzymes, including MMPs (Machein
and Conca, 1997; Amorino and Hoover, 1998). Lym-
phoid cell extravasation into perivascular tissues dur-
ing inflammation involves transmigration through the
endothelial cell layer and basement membrane, and
employement of adhesion mechanisms prior to degra-
dation of the ECM, which are similar to the process of
extravasation adopted by metastatic cells (Weeks et
al., 1993; Madri et al., 1996; Di Girolamo et al., 1998;
Trocme et al., 1998).
In the present study, we investigated human lym-
phoid tumor cells of B-cell and T-cell lineage for their
invasive potential in well-defined clinical models of
tumor progression.
RESULTS
MMP-2 and MMP-9 Expression and Production
by Human Lymphoid Tumor Cells
SB (B-cell lymphoblastic leukemia), U266 (multiple
myeloma), CEM and Jurkat (T-cell lymphoblastic
leukemia) cell lines were evaluated for expression of
MMP-2 and MMP-9 mRNA by in situ hybridization
(Fig. 1). As summarized in Table I, SB and U266
cells co-expressed the mRNAs. The signal intensity
for both mRNAs was similar in the B-lymphoblastic
leukemia cell line SB, while U266 cells showed a
more intense MMP-2 mRNA-related signal than that
of MMP-9. The T-cell lymphoblastic leukemia cell
lines CEM and Jurkat expressed only MMP-2 mRNA.
The mRNAs were activated, given the fact that the
enzymes were secreted into the cell culture condi-
tioned medium (CM) and detected by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis
(PAGE) gelatin-zymography (Fig 2). MMP-2 andPROTEOLYSIS BY LYMPHOID TUMORS 79
FIGURE In situ hybridization for MMP-2 mRNA in human lymphoid tumor cells. Easily visualized (2+) signal for (A) SB (B-cell lympho-
blastic leukemia), (B) U266 (multiple myeloma) and (C) Jurkat (T-cell lymphoblastic leukemia) cell lines. (D) Negative control in the SB
cell line. Original magnifications" (A), (C), (D) 750x; (B) 300x
MMP-9 gave rise to gelatinolytic bands with an
apparent Mr of 62 kDa and 88 kDa respectively
(panel A), indicating that both enzymes were present
in their cleaved, activated form (Huhtala et al., 1991).
According to in situ hybridization pictures, the com-
puterized image analysis of the bands (panel. B)
showed that overlapping amounts of MMP-2 and
MMP-9 were present in the CM of SB cells, whereas
MMP-2 levels were higher than those of MMP-9 in
the CM ofU266 cells, and the CM ofCEM and Jurkat
cells contained only MMP-2 gelatinolytic activity.
Overall results demonstrate that human lymphoid
tumor cells constitutively produce significant
amounts of the ECM-degrading enzymes MMP-9
and/or MMP-2, which are found in their cleaved, acti-
vated form.
MMP-2 and MMP-9 Production by Bone Marrow
Plasma Cells in Patients with Plasma Cell Tumors
To assess the invasive potential of bone marrow
plasma cells during tumor progression, patients with
plasma cell tumors at different progression stages
were studied (Vacca et al., 1999), namely: i) patients
with monoclonal gammopathies of under termined
significance (MGUS); ii) patients with non-active
multiple myeloma (MM), i.e. those in post-treatment
complete/objective response or in the off-treatment
plateau-phase; iii) patients with active MM (the pro-
gression stage), i.e. those at diagnosis with sympto-
matic disease and an increase in M-component level
in the 3 months before analysis, or at relapse, or with
















FIGURE 2 MMP-2 and MMP-9 secretion by human lymphoid
tumor cells. (A) SDS-PAGE gelatin-zymography of the CM of SB,
U266, CEM and Jurkat cell lines. Note the white bands against a
dark background with an apparent Mr of 62 kDa and 88 kDa related
to the gelatinolytic regions of activated (cleaved) MMP-2 and
MMP-9 respectively. (B) quantitations of the intensity of the bands
as optical density (O.D.), by using computerized image analysis
mic progression). Control subjects were patients with
benign anemia (due to iron or vitamin B12 defi-
ciency).
TABLE In situ hybridization for MMP-2 and MMP-9 mRNA
expression by human lymphoid tumor cell lines
mRNA of
Cell line




a. (-), no signal; (+), detectable signal; (2+), easily visualized sig-
nal.
As shown in Fig. 3, bone marrow plasma cells
expressed the MMP-2 and MMP-9 mRNA (panels A
to G), whereas in plasma cells from a control subject
the MMP-2 mRNA was absent (panel H) or poorly
expressed in some instances, as evaluated by in situ
hybridization. The MMP-2 mRNA-related signal was
stronger in patients with activeMM (panel C) than in
those with non-activeMM (panel E) and with MGUS
(panel G). The MMP-9 mRNA-related signal was
lower than that of MMP-2 in all patient groups and
overlapped between the groups (panels B, D, F).
According to in situ hybridization results, SDS-
PAGE gelatin-zymography of plasma cell CM
(Fig. 4) showed that cells secrete activated MMP-2
(62 kDa form) and lower levels of activated MMP-9
(88 kDa form), whereas those from control subjects
secrete only marginal levels of activated MMP-2 (not
shown). Specifically, quantitation of MMP-2 and
MMP-9 by computerized image analysis of the gelati-
nolytic bands showed that MMP-2 was present in CM
of 84% activeMM patients at 22.5 + 7.4 x 103 optical
density (O.D.), compared with 27% non-active MM
patients at 12.4 + 3.6 103 O.D., 25% MGUS
patients at 13.4 + 5.4 103 O.D., and 16% control
subjects at 4.0 + 1.7 103 O.D. MMP-9 was
co-secreted in 23% active MM patients, 16%
non-active MM patients and 10% MGUS patients at
lower levels than MMP-2 and at overlapping levels
between patient groups.
Overall results confirm the findings obtained in the
MM cell line U266 and demostrate that in MM
patients MMP-2 is overexpressed and secreted in step
with tumor progression.
MMP-2 and MMP-9 Expression by Mycosis
Fungoides
To assess the ability of tumor T-cells to invade the
ECM through the production ofMMPs, we studied 57
biopsies of mycosis fungoides (MF) divided into
three groups, i.e. patch, plaque and nodular (most
advanced) groups, in accordance with histopathologi-
cal diagnostic criteria for the disease (Willemze et al.,
1994). The patch stage includes tumors formed by
clustered lymphoid tumor T-cells within epidermisPROTEOLYSIS BY LYMPHOID TUMORS 81
FIGURE 3 (A), (B) Bone marrow sections from a patient with active MM (relapse), and enriched bone marrow plasma cells isolated from
patients with (C), (D) active MM (same patients as in [A], [B]), (E), (F) non-active MM (complete remission), (G) MGUS, and (H) from a
control subject with pernicious anemia, tested with in situ hybridization for MMP-2 mRNA and MMP-9 mRNA. Note (A) numerous scat-
tered plasma cells reactive for MMP-2 mRNA, whereas (B) fewer plasma cells were reactive for MMP-9 mRNA in the bone marrow of the
active MM patient. These isolated and cytocentrifuged plasma cells were (C) strongly reactive for MMP-2 mRNA and (D) less reactive for
MMP-9 mRNA. Also note (E) the weaker MMP-2 mRNA expression and (F) MMP-9 mRNA expression in the non-activeMM patient, (G)
the weak expression of MMP-2 mRNA in the MGUS patient and (H) no expression of MMP-2 mRNA in the control subject. Original mag-
nifications: (A), (B), 125x, (C)-(H) 750x (see Color Plate VI at the back of this issue)82 ANGELO VACCA et al.
and superficial dermis, whereas the plaque stage
refers to clustered and scattered cells within the epi-
dermis and dermis, and nodular stage to clustered and
scattered cells within epidermis and dermis in depth.
The S-phase tumor growth fraction rises in the transi-
tion from one step to the next (Willemze et al., 1994).
The percentages ofMF lesions expressing MMP-2
or MMP-9 mRNA and co-expressing both mRNAs
increased in parallel with tumor progression (Table
II). Compared to the patch stage, the plaque and even
more the nodular stages gave significantly higher per-
centages of lesions expressing the MMP-2 mRNA
(p<0.05 by chi-squared test), the MMP-9 mRNA
(p<0.05) and both mRNAs (p<0.05).
The intensity of expression ofMMP-2 and MMP-9
mRNA was assessed by the following score sistem:
(weak intensity), 2 (moderate), 3 (strong). The fre-
quency of tumors scoring or 2 remained fairly con-
stant in all stages. By contrast, score 3 for both
mRNAs occurred with significantly higher frequency
in relation with tumor upstaging. For MMP-2 mRNA,
it was detected in 18% of patch stage tumors, and in
31% and 52% of plaque and nodular stage tumors
respectively (p<0.05). For MMP-9, score 3 was
absent in the patch stage, whereas it was found in
13% and 31% of the plaque and nodular stage tumors
respectively (p<0.05).
Histologically, the MMP-2 and MMP-9 mRNAs
produced a cytoplasmic staining pattern (Fig. 5). In
all MF stages, the mRNAs were not expressed homo-
geneously by the entire tumor cell population, but
they were expressed by single cells or nests randomly
scattered in the tumor area, which gave a very hetero-
geneous "ground-glass-like" staining pattern (panel
A-D). These RNAs were generally not expressed by
identical subpopulations of tumor cells. The location
of positive cells was independent of the skin struc-
tures, such as hair follicles, vessels or glands, or of the
skin layer (panel C).
In all stages, the mRNAs were also found in some
stromal cell populations: MMP-2 mRNA in endothe-
lial cells of intratumor and peritumor vessels and in
fibroblasts, especially located in the stroma within or
around the tumor clusters (panel E), MMP-9 in a sub-
population of tissue macrophages (identified with
CD68 staining) frequently associated to tumor clus-
ters. In contrast to MF lesions, the normal skin used
as control expressed the MMP-2 mRNA in few
microvascular endothelial cells and in none of the
MMP-9 mRNA.
DISCUSSION
Solid tumors are able to invade the ECM by means of
matrix-degrading enzymes such as metalloproteinases
and serine-proteases (Johnson et al., 1998). Here we
report that lymphoid tumor B-cells and T-cells display
similar capacity related to the production of MMP-2
and, to a lesser extent, of MMP-9.
88kDa
,- 62 k Da
62 kDa
FIGURE 4 MMP-2 and MMP-9 secretion by bone marrow plasma
cells in patients with non-active MM and active MM. The patients
with non-activeMM were in complete remission, those with active
MM were at relapse (top) and at diagnosis (bottom). SDS-PAGE
gelatin zymography of plasma cell CM sample. Note the bands of
62 kDa and 88 kDa corresponding to the activated form of MMP-2
and MMP-9 respectively. More intense MMP-2-related activity and
MMP-9-related activity are evident in the activeMM patients. The
MMP-2-related activity is the highestPROTEOLYSIS BY LYMPHOID TUMORS 83
TABLE II Percent of positive lesions for the expression of MMP-2




n 16 n 22 n 19
MMP-2 37.5 59.1 78.9
MMP-9 12.5 31.8 52.6
MMP-2 and MMP-9 6.3 22.7 42.6
a. Data expressed as percentages of lesions.
In human lymphoid tumor cell lines SB (B-cell
lymphoblastic leukemia), U266 (multiple myeloma),
CEM and Jurkat (T-cell lymphoblastic leukemia), the
expression of MMP-2 and MMP-9 was demonstrated
at the mRNA level through in situ hybridization,
while the constitutive secretion of the enzymes was
detected in the CM through the demonstration of the
specific gelatinolytic activity. Other forms of human
blood cancer, such as granulocytic sarcoma (Koba-
yashi et al., 1995), myeloid leukemia (Ries et al.,
1994) and Burkitt’s lymphoma (Kossakowska et al.,
1996; Vacca et al., 1998) are able to secrete MMPs
costitutively or after stimulation with phorbol ester
(Ries et al, 1994; Watnabe et al, 1997).
Both MMPs are secreted in their activated, cleaved
form. In fact, MMP-2 has an Mr of 72 kDa and
MMP-9 an Mr of 92 kDa (Mignatti and Rifkin, 1993),
while we found the 62 kDa and 88 kDa cleaved forms
respectively in the CM. It is likely that, having been
secreted as proenzymes, MMPs are rapidly cleaved at
the cellular membrane level by the membrane-type
MT-MMP (Butler et al, 1997), with which lymphoid
tumor cells could be equipped. Since the lymphoblas-
toid cells secrete activated MMP-2 and MMP-9, as
well as urokinase-type plasminogen activator (uPA)
(Mignatti and Rifkin, 1993), and since these enzymes
lyse the collagens and fibronectin, which are suben-
dothelial basement membrane and interstitial stroma
ECM constituents, it is conceivable that these cells
are capable of invading the stroma and the vessel wall
and, partly by this way, are liable to enter the circula-
tion. This would enable them to enter distant body
sites via the same mechanisms.
As observed for tumor cells from invasive and met-
astatic solid tumors (Weidner, 1998), the bone mar-
row plasma cells of active MM patients express and
secrete high levels of MMP-2 (Vacca et al., 1999). In
some patients, sizeable levels of MMP-9 were
co-expressed and co-secreted. As the progression
from in situ to invasive and metastatic solid tumors is
accompanied and enhanced by secretion of proteo-
lytic enzymes (Johnson et al., 1998), our findings sug-
gest that activeMM may represent the invasive phase
of plasma cell tumors. Typically, the plasma cell
MMPs were observed in the CM in their cleaved
form. Also for tumor plasma cells, it is likely that the
secreted MMPs are rapidly cleaved and activated by
the MT-MMP system on the cell surface.
Others (Barill6 et al., 1997) have shown production
of MMP-9 by an array ofMM cell lines (prominently
by RPMI-8226 cell line) and freshly isolated bone
marrow plasma cells ofMM patients, though no cor-
relation with disease activity has been found. It has
also been shown that bone marrow stromal cells (i.e.
fibroblasts and osteoblasts) of MM patients produce
constitutively MMP-1 and the MMP-2 proenzyme
which is converted into active MMP-2 in co-cultures
with MM plasma cells (Barill6 et al., 1997). Further-
more, IL-I and TNF-c, i.e. cytokines produced by
MM plasma cells and stromal cells respectively (Mer-
ico et al., 1993; Klein, 1995), enhance MMP- 1 pro-
duction. Still other studies describe the stimulating
role of IL-I on the production of MMPs by bone
marrow stromal cells (Guedez et al., 1996).
Hence, in addition to the production of MMP-2,
which is greater in active MM, and of MMP-9 by the
MM plasma cells, there is a production of MMP-1
and MMP-2 by the bone marrow stromal cells stimu-
lated (via IL-I[3?) by the plasma cells themselves.
Given the ability of MMP-1 to degrade type I colla-
gen and ofMMP-2 and MMP-9 to degrade type IV, V,
VII and X collagens as well as fibronectin (Mignatti
and Rifkin, 1993; Johnson et al, 1998), the data sug-
gest that plasma cells of activeMM patients are espe-
cially capable of invading both the stroma and the
basement membrane of the ECM. In addition, the
degradation of ECM brings about the release of ang-
iogenic factors that are stored inside it (Mignatti and84 ANGELO VACCA et al.
FIGURE 5 Mycosis fungoides: (A), (F) plaque stage (B)-(E) nodular stage, tested by in situ hybridization for (A)-(C), (E) MMP-2 mRNA
and (D) MMP-9 mRNA. The colorimetric signal is present in most tumor cells both in the plaque and nodular stages. Note sub (A) scattered
tumor cells in superficial dermis and epidermis, sub (B)-(D) clustered tumor cells in the deep dermis and sub (C) around vascular structures.
The signal produces a "ground-glass-like" picture, expecially sub (D). Note sub (E) intense signal for MMP-2 mRNA in spindle-shaped
fibroblasts (arrows) within the tumor cells. The negative control for MMP-2 is sub (F) in an adjacent section. Original magnifications:
(A)-(F) 300x (see Color Plate VII at the back of this issue)PROTEOLYSIS BY LYMPHOID TUMORS 85
Rifkin, 1993), though plasma cells are able to secrete
angiogenic factors in active MM (Vacca et al., 1999).
Thus, overall data suggest that major proteolytic
activity and angiogenesis occur together in close
vicinity of plasma cells, and that conditions of intra-
and extramedullary disseminations of the plasma cells
themselves are thereby established.
Along with MM plasma cells, malignant B cells in
non-Hodgkin’s lymphomas have been shown to be an
important source of MMP-2, MMP-9 (Stetler-Steven-
son et al., 1997; Kossakowska et al., 1998) and uPA
(Philip-Joet et al., 1995). The proteolytic activity con-
nected with such enzymes is thought to be responsible
for the extensive permeation of organs, with destruc-
tion of their anatomical boundaries in a fashion simi-
lar to that observed in carcinomas (Kossakowska et
al., 1996; 1998).
In MF, the production of MMPs increases in step
with progression stages. MMP-2 and MMP-9 mRNAs
are significantly upregulated from patch to nodular
stage, as indicated by more frequent tumors express-
ing one or both mRNAs and more frequent tumors
showing the strongest expression intensity in the nod-
ular stage. Thus, both MMPs are produced more fre-
quently and in greater’ quantities with advancing MF
progression, suggesting that a more intense degrada-
tion of interstitial stroma and subendothelial base-
ment membrane takes place with progression. This
may explain the greater dissemination and deepening
ofMF cells into dermis as the disease progresses from
the patch to the nodular stage, and accounts, together
with denser angiogenesis in the plaque and even more
in the nodular stage (Vacca et al., 1997), for frequent
spreading ofMF cells in lymph nodes, and parenchy-
mal organs during these stages. Finally, MMP-2
mRNA was detected in microvascular endothelial
cells and fibroblasts, whereas MMP-9 mRNA was
seen in a subset of macrophages. By contrast, in nor-
mal skin only MMP-2 mRNA was expressed by few
microvascular endothelial cells. Thus, the expression
of MMPs by stromal cells characterize the malignant
condition, and agree with findings in solid tumours
(Polverini, 1996; Leek et al., 1997; Ribatti et al.,
1999). Stromal cells, probably recruited and activated
by MF cells, produce the MMPs, thus participating in
the degradation of the extracellular matrix and con-
tributing to the tumor dissemination. Therefore, regu-
lation of ECM degradation during tumor progression
is the result of a concerted action, not only of several
proteolytic systems, but also of several cell types,
including both malignant and non-malignant cells in
tumor stroma.
Overall, our results may explain the frequent occur-
rence of extranodal or extramedullary localizations in
human lymphoproliferative diseases, and suggest that
combination therapy with protease inhibitors plus
cytotoxic drugs successfully applied in animal solid
tumors (Folkman, 1996; Stetler-Stevenson, 1999)
could perhaps be considered in these diseases.
MATERIAL AND METHODS
Cell Lines and Preparation of Conditioned
Medium (CM)
SB, CEM, Jurkat and U266 cell lines were obtained
from the American Type Culture Collection (Rock-
ville, MD, USA) and grown in RPMI-1640 medium
supplemented with 10% heat inactivated calf serum
(FCS) and 1% glutamine at 37C in 5% CO2 humidi-
fied atmosphere. After culturing for 24 h in medium
without FCS (serum free medium- SFM), the condi-
tioned medium (CM) was collected, sequentially cen-
trifuged at 1,200 and 12,000 rpm for 10 min
respectively, filtered through sterilized 0.22 tm
pore-size filters (Costar, Cambridge, MA), and stored
at -80C.
Bone Marrow Plasma Cell Cultures
Aspirates were subjected to Ficoll-Hypaque density
gradient centrifugation and plasma cell enrichment. T
cells were removed by two-fold E-rosetting, mono-
cytes and fibroblasts by adhesion determined by cul-
turing in plastic flasks for 90 min in RPMI-1640
containing 10% FCS at 37C in 5% CO2 humidified
atmosphere. Residual cells were incubated with mag-
netic beads (Dynal, Oslo, Norway) coated with anti-86 ANGELO VACCA et al.
body to the plasma cell marker CD38 (Becton &
Dickinson, Mountain View, CA). After magnetic sub-
traction and bead detachment by culturing cells for 12
h in RPMI-1640 supplement d with 10% FCS at 37C
in 5% CO2 humidified atmosphere, enriched plasma
cells were obtained. These cells contained <2% of T
cells and monocytes, as assessed by flow cytometry
and with the anti-CD3 and anti-CD68 antibodies
respectively (FACScan, Becton & Dickinson) and
consisted of >95% tumor plasma cells and their clon-
ally-related cells (Billadeau et al., 1993), as assessed
by morphology with May-Grtinwald-Giemsa and
flow cytometry with the anti-CD38 antibody (Becton
& Dickinson). Cells were cultured (1 x 107 per 25
cm2 flask) for 24 h in SFM, and their viability
assessed by trypan blue exclusion was >90%. The
plasma cell CM was prepared as described above.
MMP-2 and MMP-9 sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (PAGE)
gelatin-zymography
SDS-PAGE gelatin-zymography of CM was per-
formed to visualize the gelatinolytic activity of the
secreted MMP-2 and MMP-9 (Albini et al., 1987).
Ten gg of CM proteins were applied to 7.5%
SDS-PAGE gels co-polymerized with type A gelatin
from porcine skin (Sigma Chemical Co., St. Louis,
MO) at a final concentration of 0.6 mg/ml. After elec-
trophoresis, gels were washed in 2.5% Triton lx for 1
h to remove SDS, incubated for 18 h at 37C and
stained in 0.1% Coomassie brilliant blue. The gelati-
nolytic regions were observed as white bands against
a blue background. The levels ofMMP activity were
assessed by scoring the intensity of the bands by a
computerized image analysis (APPLE, Cupertino,
CA).
In Situ Hybridization ofMMP-2 and MMP-9
mRNA
This was performed as described previously (Vacca et
al., 1997; 1998). Cytocentrifuged plasma cells (1-2 x
105 per slide) were fixed in 4% paraformaldehyde,
washed in phosphate-buffered saline (PBS), made
permeable with 10 gg/ml of proteinase K (Sigma
Chemical Co.) in CaC12 (2 mM)-tris(hydroxyme-
thyl)aminomethane (TRIS) (20 mM) for 5 min at
37C, acetylated with 0.25% acetate in 0.1 M trieth-
anolamine, washed in 2x standard saline citrate
(SSC), dehydrated in graded ethanols and air-dried.
Cells were hybridized overnight at 50C with 5 gg/ml
of two 5’-biotinylated oligonucleotides (Genenco Life
Sciences, Florence, Italy), the first of 42 bases com-
plementary to the ninth exon sequence 446-459 of the
MMP-2 mRNA, the second of 48 bases complemen-
tary to the ninth exon sequence 445-460 of the
MMP-9 mRNA (Huhtala et al., 1991). Fifty percent
deionized formamide, 600 mM NaC1, 80 mM TRIS,
4 mM EDTA, 10 mM dithiothreitol, lx Denhardt’s
Solution and 100 gg/ml salmon sperm DNA were
used as hybridization medium. After washing in 2x to
0.01x SSC and in PBS, cytospins were incubated
overnight at 4C with streptavidin-alkaline phos-
phatase conjugate (Promega Co., Madison, WI). After
alkaline phosphatase activity was revealed by West-
ern blue stabilized substrate (Promega Co.), cytospins
were mounted in buffered glycerin and evaluated by
two observers with a double-headed Leitz Dialux 20
photomicroscope (Leitz, Wetzlar, Germany). Cells
were scored positive for the hybridization signal rela-
tive to the background signal of RNAse-treated con-
trol cytospins hybridized with the same
oligonucleotides as follows: (-), no signal; (+), detect-
able signal; (2+), easily visualized signal. For MF tis-
sues, deparaffinized sections processed as described
above were used. After detection of alkaline phos-
phatase activity by Western blue stabilized substrate
(Promega Co.), sections were mounted in buffered
glycerine, and then evaluated by two investigators
under the photomicroscope for the extent and inten-
sity of the hybridization signal within the tumor area.
The signal was scored relative to the background sig-
nal of RNAse-treated sections hybridized with the
same oligonucleotides (negative controls) as follows:
(1) weak (detectable), (2) moderate (easily visualised)
or (3) strong. MF were considered positive when
>10% of tumor cells gave the signal. Negative MF
(scored as 0) were those with <10% of tumor cellsPROTEOLYSIS BY LYMPHOID TUMORS 87
displaying the signal. The cut-off was based on the
finding that <10% of tumor cells seldom gave the sig-
nal in negative controls.
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